BRPI1013152A2 - composto que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais. - Google Patents
composto que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais.Info
- Publication number
- BRPI1013152A2 BRPI1013152A2 BRPI1013152A BRPI1013152A BRPI1013152A2 BR PI1013152 A2 BRPI1013152 A2 BR PI1013152A2 BR PI1013152 A BRPI1013152 A BR PI1013152A BR PI1013152 A BRPI1013152 A BR PI1013152A BR PI1013152 A2 BRPI1013152 A2 BR PI1013152A2
- Authority
- BR
- Brazil
- Prior art keywords
- activity
- muscle
- urethal
- sphincters
- destructive
- Prior art date
Links
- 230000000694 effects Effects 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001066 destructive effect Effects 0.000 title 1
- 210000003205 muscle Anatomy 0.000 title 1
- 230000004118 muscle contraction Effects 0.000 title 1
- 230000002040 relaxant effect Effects 0.000 title 1
- 210000005070 sphincter Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009139657 | 2009-06-10 | ||
| JP2009-139657 | 2009-06-10 | ||
| JP2009-256008 | 2009-11-09 | ||
| JP2009256008 | 2009-11-09 | ||
| PCT/JP2010/059771 WO2010143661A1 (ja) | 2009-06-10 | 2010-06-09 | 膀胱排尿筋収縮および尿道括約筋弛緩作用を有する化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1013152A2 true BRPI1013152A2 (pt) | 2016-04-05 |
| BRPI1013152B1 BRPI1013152B1 (pt) | 2019-06-18 |
Family
ID=43308916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013152-3A BRPI1013152B1 (pt) | 2009-06-10 | 2010-06-09 | Composto, composição farmacêutica e medicamento que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8410281B2 (pt) |
| EP (1) | EP2441760B1 (pt) |
| JP (1) | JP4807478B2 (pt) |
| KR (1) | KR101633149B1 (pt) |
| CN (1) | CN102803239B (pt) |
| AU (1) | AU2010259585B2 (pt) |
| BR (1) | BRPI1013152B1 (pt) |
| CA (1) | CA2764782C (pt) |
| DK (1) | DK2441760T3 (pt) |
| ES (1) | ES2444500T3 (pt) |
| IL (1) | IL216856A0 (pt) |
| MX (1) | MX2011013283A (pt) |
| NZ (1) | NZ596960A (pt) |
| PL (1) | PL2441760T3 (pt) |
| PT (1) | PT2441760E (pt) |
| RU (1) | RU2531350C2 (pt) |
| TW (1) | TWI437987B (pt) |
| WO (1) | WO2010143661A1 (pt) |
| ZA (1) | ZA201109103B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1013152B1 (pt) * | 2009-06-10 | 2019-06-18 | Ono Pharmaceutical Co., Ltd. | Composto, composição farmacêutica e medicamento que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais |
| AU2013309872B2 (en) | 2012-08-31 | 2017-09-14 | Ono Pharmaceutical Co., Ltd. | Amine salt and crystals thereof |
| CA2918245C (en) | 2013-08-01 | 2022-08-30 | Dignify Therapeutics, Inc. | Compositions and methods for inducing urinary voiding and defecation |
| JP2017533227A (ja) * | 2014-11-03 | 2017-11-09 | ウィリアム・ボーモント・ホスピタルWilliam Beaumont Hospital | 低活動膀胱症候群を治療するための方法 |
| AR117551A1 (es) | 2018-12-31 | 2021-08-11 | Adama Makhteshim Ltd | Síntesis de 1,1,2-trifluoro-4-(sulfonil sustituido)-but-1-eno |
| MX2022001388A (es) * | 2019-08-04 | 2022-03-25 | Yeda Res & Dev | Proceso para la preparacion de fluensulfona. |
| CN119039235B (zh) * | 2024-08-20 | 2025-12-16 | 湖北省医药工业研究院有限公司 | 合成阿伐那非、中间体的方法及用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS503362B1 (pt) | 1970-06-10 | 1975-02-04 | ||
| JPS5231404B1 (pt) | 1971-04-28 | 1977-08-15 | ||
| JPS57156460A (en) | 1981-03-20 | 1982-09-27 | Ono Pharmaceut Co Ltd | Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation |
| JPS60197667A (ja) | 1984-03-19 | 1985-10-07 | Ono Pharmaceut Co Ltd | 6―ケト―プロスタグランジン類似化合物及びその製造方法 |
| KR20000070903A (ko) | 1997-02-10 | 2000-11-25 | 오노 야꾸힝 고교 가부시키가이샤 | 11,15-o-디알킬프로스타글란딘 e 유도체, 이것의 제조 방법 및 이것을 유효 성분으로 함유하는 약제 |
| JPH11130678A (ja) | 1997-08-27 | 1999-05-18 | Kaken Pharmaceut Co Ltd | 神経圧迫による神経障害改善剤 |
| IL159996A0 (en) | 2001-07-23 | 2004-06-20 | Ono Pharmaceutical Co | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| JP2005053707A (ja) | 2001-07-30 | 2005-03-03 | Kankyo Device Kenkyusho:Kk | 可視光応答性材料の製造方法 |
| JP4547912B2 (ja) | 2002-03-05 | 2010-09-22 | 小野薬品工業株式会社 | 8−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| US7551916B2 (en) | 2002-07-11 | 2009-06-23 | Nokia Corporation | Method and device for automatically changing a digital content on a mobile device according to sensor data |
| JP4582456B2 (ja) | 2003-01-21 | 2010-11-17 | 小野薬品工業株式会社 | 8−アザプロスタグランジン誘導体およびその医薬用途 |
| US20070167403A1 (en) | 2003-04-03 | 2007-07-19 | Yoshifumi Takenobu | Remedy for spinal canal stenosis |
| US7833995B2 (en) | 2003-12-05 | 2010-11-16 | Ono Pharmaceutical Co., Ltd. | Blood flow promoters for cauda equina tissues |
| JPWO2005061492A1 (ja) | 2003-12-22 | 2007-07-12 | 小野薬品工業株式会社 | 含窒素複素環化合物およびそれらを有効成分とする薬剤 |
| WO2006016689A1 (ja) | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
| JP4893999B2 (ja) | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
| JP2006129788A (ja) | 2004-11-05 | 2006-05-25 | Nippon Starch Chemical Co Ltd | 揚げ物用ミックス |
| CA2610692C (en) * | 2005-06-03 | 2014-11-25 | Ono Pharmaceutical Co., Ltd. | Ep2 agonists which may have an ep3 agonistic effect for regeneration and/or protection of nerves |
| JP5630264B2 (ja) * | 2008-06-06 | 2014-11-26 | 小野薬品工業株式会社 | 膀胱排尿筋収縮および尿道括約筋弛緩剤 |
| BRPI1013152B1 (pt) * | 2009-06-10 | 2019-06-18 | Ono Pharmaceutical Co., Ltd. | Composto, composição farmacêutica e medicamento que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais |
-
2010
- 2010-06-09 BR BRPI1013152-3A patent/BRPI1013152B1/pt not_active IP Right Cessation
- 2010-06-09 CA CA2764782A patent/CA2764782C/en active Active
- 2010-06-09 ES ES10786192.4T patent/ES2444500T3/es active Active
- 2010-06-09 DK DK10786192.4T patent/DK2441760T3/en active
- 2010-06-09 TW TW099118684A patent/TWI437987B/zh not_active IP Right Cessation
- 2010-06-09 MX MX2011013283A patent/MX2011013283A/es active IP Right Grant
- 2010-06-09 AU AU2010259585A patent/AU2010259585B2/en not_active Ceased
- 2010-06-09 PL PL10786192T patent/PL2441760T3/pl unknown
- 2010-06-09 US US13/377,047 patent/US8410281B2/en not_active Expired - Fee Related
- 2010-06-09 NZ NZ596960A patent/NZ596960A/xx not_active IP Right Cessation
- 2010-06-09 EP EP10786192.4A patent/EP2441760B1/en active Active
- 2010-06-09 JP JP2011503274A patent/JP4807478B2/ja active Active
- 2010-06-09 PT PT107861924T patent/PT2441760E/pt unknown
- 2010-06-09 WO PCT/JP2010/059771 patent/WO2010143661A1/ja not_active Ceased
- 2010-06-09 KR KR1020117029571A patent/KR101633149B1/ko not_active Expired - Fee Related
- 2010-06-09 CN CN201080035423.7A patent/CN102803239B/zh not_active Expired - Fee Related
- 2010-06-09 RU RU2011152927/04A patent/RU2531350C2/ru active
-
2011
- 2011-12-08 IL IL216856A patent/IL216856A0/en active IP Right Grant
- 2011-12-09 ZA ZA2011/09103A patent/ZA201109103B/en unknown
-
2013
- 2013-03-04 US US13/784,008 patent/US8716490B2/en active Active
-
2014
- 2014-02-12 US US14/178,901 patent/US9150528B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010259585A1 (en) | 2012-01-19 |
| EP2441760A1 (en) | 2012-04-18 |
| ZA201109103B (en) | 2012-08-29 |
| US20130184236A1 (en) | 2013-07-18 |
| BRPI1013152B1 (pt) | 2019-06-18 |
| JP4807478B2 (ja) | 2011-11-02 |
| HK1169117A1 (en) | 2013-01-18 |
| US8716490B2 (en) | 2014-05-06 |
| PT2441760E (pt) | 2014-01-07 |
| TWI437987B (zh) | 2014-05-21 |
| RU2531350C2 (ru) | 2014-10-20 |
| EP2441760B1 (en) | 2013-11-20 |
| WO2010143661A1 (ja) | 2010-12-16 |
| US8410281B2 (en) | 2013-04-02 |
| IL216856A0 (en) | 2012-03-01 |
| JPWO2010143661A1 (ja) | 2012-11-29 |
| US9150528B2 (en) | 2015-10-06 |
| AU2010259585B2 (en) | 2015-11-19 |
| US20120088805A1 (en) | 2012-04-12 |
| CN102803239A (zh) | 2012-11-28 |
| MX2011013283A (es) | 2012-01-12 |
| KR101633149B1 (ko) | 2016-06-23 |
| NZ596960A (en) | 2013-04-26 |
| PL2441760T3 (pl) | 2014-05-30 |
| TW201103539A (en) | 2011-02-01 |
| DK2441760T3 (en) | 2014-02-17 |
| CA2764782C (en) | 2017-07-25 |
| CN102803239B (zh) | 2015-04-15 |
| EP2441760A4 (en) | 2012-12-05 |
| ES2444500T3 (es) | 2014-02-25 |
| CA2764782A1 (en) | 2010-12-16 |
| KR20120026088A (ko) | 2012-03-16 |
| US20140171387A1 (en) | 2014-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201600273B (it) | Genz 112638 per trattare la malattia di gaucher o fabry in terapia di combinazione | |
| BRPI0908030A2 (pt) | Corpo roscado de extremidade dupla e corpo internamente roscado | |
| EP2513023A4 (en) | COMPOSITIONS OF CIS-1,1,1,4,4,4-HEXAFLUOR-2-BUTENE AND ITS USES | |
| BRPI1013152A2 (pt) | composto que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais. | |
| BR112013013402A2 (pt) | combinações de ingredientes ativos que compreendem piridiletilbenzamidas e outros ingredientes ativos | |
| BRPI1013503A2 (pt) | formulação de iniciador não cromado que inibe corrosão, e, estrutura | |
| BRPI1013705A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica | |
| AP2013006984A0 (en) | BicycloÄ3.2.1Üoctyl amide derivatives and uses of same | |
| EP2432492A4 (en) | APPLICATION AND USE OF PRG4 AND THERAPEUTIC MODULATION THEREOF | |
| IT1403381B1 (it) | Braccio trasversale e procedimento per la realizzazione di un braccio trasversale. | |
| ZA201100560B (en) | Pest-control compositions and methods having high target and low non-target activity | |
| ZA201301231B (en) | Treatment of l-dopa,dopamine agonist and/or dopamine enhancer induced disorders | |
| GB2497453B (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| EP2393836A4 (en) | SAM-6 VARIANTS, TARGET AND METHODS OF USING SAME | |
| PL388575A1 (pl) | Nowy 7-O-β -D-4'''metoksyglukopiranozyd 8-prenylonaringeniny i sposób jego wytwarzania | |
| BR112012003026A2 (pt) | formulações e métodos de emprego de desinfetante anidro. | |
| FR2927632B1 (fr) | Cornee et muqueuse reconstruites. | |
| IT1397183B1 (it) | Dispositivo e procedimento per definire la posizione di un oggetto | |
| BRPI0922581A2 (pt) | pateamento de arame de aço em estanho e o arame de aço daí resultante. | |
| PL388612A1 (pl) | Nowa 7-O-n-pentylo-8-prenylonaringenina oraz sposób jej otrzymywania | |
| BR112012018072A2 (pt) | formulação anidra, método e utilização da formulação | |
| Fields | The psychology of pain | |
| ES1071894Y (es) | Protector muscular | |
| PL2654752T3 (pl) | Pochodne diarylopirydazynonów, ich wytwarzanie, i ich zastosowanie do leczenia ludzi | |
| IT1398845B1 (it) | Composizione per la prevenzione e/o il trattamento della fatica muscolare |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2010, OBSERVADAS AS CONDICOES LEGAIS |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2778 DE 02-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |